Apealea (paclitaxel)
- Region
- 🇪🇺 EU
- Active substance
- paclitaxel
- Company
- Inceptua AB
- Status
- Withdrawn
- Therapeutic area
- Ovarian Neoplasms
- CHMP opinion
- Thu 20 Sep 2018
- EU approval
- Tue 20 Nov 2018
- Application
- EMEA/H/C/004154
- ATC
- L01CD01
- Official record
- www.ema.europa.eu
Indication
Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum?sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Pazenir Authorised · ratiopharm GmbH
- 🇪🇺 Abraxane Authorised · Bristol-Myers Squibb Pharma EEIG
- 🇪🇺 Naveruclif Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Apexelsin Authorised · Whiteoak Pharmaceutical B.V.
- 🇪🇺 Paxene Withdrawn · Norton Healthcare Ltd.
Follow Apealea
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.